Symbols / CASI $0.21 CASI Pharmaceuticals Inc
CASI Chart
Stock Fundamentals
|
|
|
|
|
|
About
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc?RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Ratings
Current target
$0.21
Low
$4.00
High
$4.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-04-09 | main | HC Wainwright & Co. | Buy → Buy | $4 |
- CASI Pharmaceuticals (CASI) director reports fully vested option stakes - Stock Titan hu, 23 Apr 2026 10
- Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low? - Stocktwits Wed, 25 Feb 2026 15
- CASI Pharmaceuticals stock plunges on Nasdaq delisting notice - Investing.com Wed, 25 Feb 2026 08
- CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ - Investing News Network hu, 27 Nov 2025 16
- Lacklustre Performance Is Driving CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) 27% Price Drop - simplywall.st ue, 25 Nov 2025 08
- CASI Pharmaceuticals Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis Wed, 24 Dec 2025 08
- Director Zeng lists CASI Pharmaceuticals (CASIF) fully vested option holdings - Stock Titan ue, 21 Apr 2026 01
- CASI Pharmaceuticals (CASIF) executive details 2034 stock option positions - Stock Titan ue, 07 Apr 2026 07
- CASI Pharmaceuticals (CASIF) CMO holds 116,333 fully vested options at $1.93 - Stock Titan Fri, 03 Apr 2026 07
- CASI Pharmaceuticals (OTC: CASIF) controller reports multiple stock option grants - Stock Titan Mon, 13 Apr 2026 20
- CASI (CASIF) General Counsel discloses vested and performance-based stock options - Stock Titan hu, 16 Apr 2026 07
- CASI loses Nasdaq listing, pursues OTC trading after panel ruling - Stock Titan Wed, 25 Feb 2026 08
- CASI Pharmaceuticals (OTCQB: CASIF) completes final $5M convertible note - Stock Titan Mon, 20 Apr 2026 13
- Leadership shift at CASI (NASDAQ: CASI) as Global CMO role ends - Stock Titan Mon, 20 Apr 2026 20
- Potential buyer offers 30% premium as CASI blood disorder drug shows promise - Stock Titan Mon, 12 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
28.54
-15.77%
|
33.88
-21.41%
|
43.11
+42.89%
|
30.17
|
| Operating Revenue |
|
28.54
-15.77%
|
33.88
-21.30%
|
43.05
+43.39%
|
30.02
|
| Cost Of Revenue |
|
17.39
+25.78%
|
13.83
-12.64%
|
15.83
+26.04%
|
12.56
|
| Reconciled Cost Of Revenue |
|
17.39
+25.78%
|
13.83
-12.64%
|
15.83
+26.04%
|
12.56
|
| Gross Profit |
|
11.15
-44.41%
|
20.05
-26.50%
|
27.28
+54.90%
|
17.61
|
| Operating Expense |
|
50.36
+11.09%
|
45.33
-15.69%
|
53.77
+1.79%
|
52.83
|
| Research And Development |
|
8.92
-9.57%
|
9.86
-38.35%
|
16.00
+10.91%
|
14.42
|
| Selling General And Administration |
|
41.44
-0.94%
|
41.84
+10.75%
|
37.77
-1.64%
|
38.41
|
| Selling And Marketing Expense |
|
17.87
+8.61%
|
16.45
+14.83%
|
14.33
-2.58%
|
14.71
|
| General And Administrative Expense |
|
23.58
-7.13%
|
25.39
+8.26%
|
23.45
-1.06%
|
23.70
|
| Other Gand A |
|
23.58
-7.13%
|
25.39
+8.26%
|
23.45
-1.06%
|
23.70
|
| Other Operating Expenses |
|
-0.00
+99.97%
|
-6.37
|
—
|
—
|
| Total Expenses |
|
67.75
+14.52%
|
59.16
-15.00%
|
69.60
+6.44%
|
65.39
|
| Operating Income |
|
-39.21
-55.11%
|
-25.28
+4.57%
|
-26.49
+24.78%
|
-35.22
|
| Total Operating Income As Reported |
|
-39.62
-57.98%
|
-25.08
+26.30%
|
-34.03
+18.03%
|
-41.52
|
| EBITDA |
|
-34.87
-54.72%
|
-22.54
+35.51%
|
-34.95
-4.63%
|
-33.40
|
| Normalized EBITDA |
|
-36.15
-79.46%
|
-20.15
-8.83%
|
-18.51
+41.97%
|
-31.90
|
| Reconciled Depreciation |
|
2.33
-37.69%
|
3.74
+54.46%
|
2.42
+33.44%
|
1.81
|
| EBIT |
|
-37.20
-41.56%
|
-26.28
+29.68%
|
-37.37
-6.11%
|
-35.22
|
| Total Unusual Items |
|
1.29
+153.85%
|
-2.39
+85.46%
|
-16.44
-992.82%
|
-1.50
|
| Total Unusual Items Excluding Goodwill |
|
1.29
+153.85%
|
-2.39
+85.46%
|
-16.44
-992.82%
|
-1.50
|
| Special Income Charges |
|
-0.22
+89.20%
|
-2.01
+81.37%
|
-10.78
-44.05%
|
-7.49
|
| Other Special Charges |
|
—
|
—
|
—
|
6.55
|
| Impairment Of Capital Assets |
|
0.70
|
0.00
-100.00%
|
8.72
|
0.00
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
—
|
6.55
|
| Write Off |
|
0.00
-100.00%
|
2.01
|
0.00
-100.00%
|
0.86
|
| Net Income |
|
-39.26
-45.73%
|
-26.94
+34.32%
|
-41.01
-11.90%
|
-36.65
|
| Pretax Income |
|
-38.07
-44.79%
|
-26.29
+29.76%
|
-37.43
-4.43%
|
-35.84
|
| Net Non Operating Interest Income Expense |
|
-0.33
-154.07%
|
0.61
+383.46%
|
0.13
-60.44%
|
0.32
|
| Interest Expense Non Operating |
|
0.87
+5706.67%
|
0.01
-75.81%
|
0.06
|
—
|
| Net Interest Income |
|
-0.33
-154.07%
|
0.61
+383.46%
|
0.13
-60.44%
|
0.32
|
| Interest Expense |
|
0.87
+5706.67%
|
0.01
-75.81%
|
0.06
|
—
|
| Interest Income Non Operating |
|
0.54
-14.31%
|
0.63
+232.80%
|
0.19
-41.12%
|
0.32
|
| Interest Income |
|
0.54
-14.31%
|
0.63
+232.80%
|
0.19
-41.12%
|
0.32
|
| Other Income Expense |
|
1.48
+190.71%
|
-1.63
+85.31%
|
-11.07
-1069.87%
|
-0.95
|
| Other Non Operating Income Expenses |
|
0.19
-75.39%
|
0.76
+1636.36%
|
0.04
-92.11%
|
0.56
|
| Gain On Sale Of Security |
|
1.50
+494.75%
|
-0.38
+93.26%
|
-5.65
-194.53%
|
5.98
|
| Tax Provision |
|
0.00
+100.00%
|
-0.08
-104.09%
|
1.98
|
0.00
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
-98.77%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-0.01
+99.82%
|
-4.11
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-39.26
-49.50%
|
-26.26
+34.77%
|
-40.26
-12.32%
|
-35.84
|
| Net Income From Continuing Operation Net Minority Interest |
|
-39.26
-45.73%
|
-26.94
+34.32%
|
-41.01
-11.90%
|
-36.65
|
| Net Income From Continuing And Discontinued Operation |
|
-39.26
-45.73%
|
-26.94
+34.32%
|
-41.01
-11.90%
|
-36.65
|
| Net Income Continuous Operations |
|
-39.26
-49.50%
|
-26.26
+34.77%
|
-40.26
-12.32%
|
-35.84
|
| Minority Interests |
|
0.00
+100.00%
|
-0.68
+10.30%
|
-0.76
+6.77%
|
-0.81
|
| Normalized Income |
|
-40.55
-65.12%
|
-24.56
+14.40%
|
-28.69
+18.39%
|
-35.15
|
| Net Income Common Stockholders |
|
-39.26
-45.62%
|
-26.96
+34.27%
|
-41.01
-11.90%
|
-36.65
|
| Diluted EPS |
|
-2.56
-26.73%
|
-2.02
+32.89%
|
-3.01
-11.90%
|
-2.69
|
| Basic EPS |
|
-2.56
-26.73%
|
-2.02
+32.89%
|
-3.01
-11.90%
|
-2.69
|
| Basic Average Shares |
|
15.34
+14.82%
|
13.36
-2.10%
|
13.65
+0.27%
|
13.61
|
| Diluted Average Shares |
|
15.34
+14.82%
|
13.36
-2.10%
|
13.65
+0.27%
|
13.61
|
| Diluted NI Availto Com Stockholders |
|
-39.26
-45.62%
|
-26.96
+34.27%
|
-41.01
-11.90%
|
-36.65
|
| Earnings From Equity Interest |
|
0.00
|
0.00
-100.00%
|
5.33
|
0.00
|
| Earnings From Equity Interest Net Of Tax |
|
-1.19
-2377.08%
|
-0.05
+94.33%
|
-0.85
|
0.00
|
| Gain On Sale Of PPE |
|
0.48
|
0.00
+100.00%
|
-2.06
-3066.15%
|
-0.07
|
| Preferred Stock Dividends |
|
—
|
0.02
|
—
|
—
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
53.67
-28.69%
|
75.27
-21.79%
|
96.23
-30.42%
|
138.30
|
| Current Assets |
|
39.58
-33.31%
|
59.34
-19.18%
|
73.42
+18.48%
|
61.97
|
| Cash Cash Equivalents And Short Term Investments |
|
16.09
-47.70%
|
30.77
-40.06%
|
51.34
+5.69%
|
48.57
|
| Cash And Cash Equivalents |
|
13.47
-21.16%
|
17.08
-63.74%
|
47.11
+21.72%
|
38.70
|
| Other Short Term Investments |
|
2.62
-80.83%
|
13.69
+223.93%
|
4.22
-57.18%
|
9.87
|
| Receivables |
|
15.35
+51.36%
|
10.14
-21.85%
|
12.97
+32.34%
|
9.80
|
| Accounts Receivable |
|
15.35
+60.66%
|
9.55
-26.38%
|
12.97
+32.34%
|
9.80
|
| Gross Accounts Receivable |
|
—
|
—
|
12.97
+32.34%
|
9.80
|
| Allowance For Doubtful Accounts Receivable |
|
—
|
—
|
0.00
|
0.00
|
| Inventory |
|
5.25
-66.92%
|
15.88
+158.67%
|
6.14
+221.87%
|
1.91
|
| Finished Goods |
|
5.25
-66.92%
|
15.88
+158.67%
|
6.14
+221.87%
|
1.91
|
| Prepaid Assets |
|
—
|
—
|
—
|
1.69
|
| Other Current Assets |
|
2.89
+12.81%
|
2.56
-13.95%
|
2.98
+76.24%
|
1.69
|
| Total Non Current Assets |
|
13.90
-12.70%
|
15.92
-30.19%
|
22.81
-70.11%
|
76.33
|
| Net PPE |
|
11.36
-2.35%
|
11.63
-12.06%
|
13.23
-39.37%
|
21.82
|
| Gross PPE |
|
17.07
+4.81%
|
16.28
+4.87%
|
15.53
-35.47%
|
24.06
|
| Accumulated Depreciation |
|
-5.71
-22.70%
|
-4.65
-102.31%
|
-2.30
-2.45%
|
-2.24
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
6.58
-1.48%
|
6.68
+438.20%
|
1.24
-28.18%
|
1.73
|
| Construction In Progress |
|
0.00
-100.00%
|
0.02
-99.60%
|
5.73
-52.64%
|
12.10
|
| Other Properties |
|
3.49
+45.99%
|
2.39
+71.10%
|
1.40
-84.65%
|
9.11
|
| Goodwill And Other Intangible Assets |
|
0.24
-87.06%
|
1.84
+73.00%
|
1.06
-91.29%
|
12.20
|
| Other Intangible Assets |
|
0.24
-87.06%
|
1.84
+73.00%
|
1.06
-91.29%
|
12.20
|
| Investments And Advances |
|
1.72
+2.08%
|
1.68
-77.48%
|
7.46
-81.40%
|
40.13
|
| Other Investments |
|
—
|
—
|
4.40
-89.04%
|
40.13
|
| Other Non Current Assets |
|
0.59
-23.37%
|
0.77
-27.46%
|
1.06
-51.52%
|
2.18
|
| Total Liabilities Net Minority Interest |
|
51.82
+1.41%
|
51.10
+74.40%
|
29.30
-3.42%
|
30.34
|
| Current Liabilities |
|
36.45
+117.94%
|
16.73
-1.64%
|
17.00
+28.96%
|
13.19
|
| Payables And Accrued Expenses |
|
14.37
+6.82%
|
13.46
-0.48%
|
13.52
+16.49%
|
11.61
|
| Payables |
|
13.04
+5.68%
|
12.34
-4.16%
|
12.87
+11.48%
|
11.55
|
| Accounts Payable |
|
2.72
-38.64%
|
4.44
+34.93%
|
3.29
+47.95%
|
2.22
|
| Other Payable |
|
8.47
+18.47%
|
7.15
-5.14%
|
7.53
-13.12%
|
8.67
|
| Dividends Payable |
|
1.85
+145.55%
|
0.75
|
0.00
|
—
|
| Current Accrued Expenses |
|
1.33
+19.32%
|
1.12
+72.53%
|
0.65
+980.00%
|
0.06
|
| Total Tax Payable |
|
—
|
0.48
-76.54%
|
2.05
+214.42%
|
0.65
|
| Income Tax Payable |
|
—
|
0.00
-100.00%
|
1.90
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
19.61
+2593.13%
|
0.73
-16.13%
|
0.87
-18.19%
|
1.06
|
| Current Debt |
|
18.39
|
—
|
—
|
—
|
| Other Current Borrowings |
|
18.39
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
1.22
+67.72%
|
0.73
-16.13%
|
0.87
-18.19%
|
1.06
|
| Current Deferred Liabilities |
|
2.47
-2.71%
|
2.54
-2.83%
|
2.62
|
—
|
| Current Deferred Revenue |
|
2.47
-2.71%
|
2.54
-2.83%
|
2.62
|
—
|
| Other Current Liabilities |
|
—
|
—
|
0.65
+24.86%
|
0.52
|
| Total Non Current Liabilities Net Minority Interest |
|
15.37
-55.29%
|
34.38
+179.56%
|
12.30
-28.31%
|
17.15
|
| Long Term Debt And Capital Lease Obligation |
|
2.54
-87.64%
|
20.51
+4209.03%
|
0.48
-56.92%
|
1.10
|
| Long Term Debt |
|
—
|
18.89
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
2.54
+56.87%
|
1.62
+239.50%
|
0.48
-56.92%
|
1.10
|
| Tradeand Other Payables Non Current |
|
1.01
-50.37%
|
2.04
|
0.00
|
—
|
| Non Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
2.83
|
| Non Current Deferred Revenue |
|
—
|
—
|
0.00
-100.00%
|
2.83
|
| Other Non Current Liabilities |
|
11.82
+0.00%
|
11.82
+0.00%
|
11.82
-10.58%
|
13.22
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
23.46
|
| Stockholders Equity |
|
1.85
-92.34%
|
24.16
-45.79%
|
44.57
-47.25%
|
84.50
|
| Common Stock Equity |
|
1.85
-92.34%
|
24.16
-45.79%
|
44.57
-47.25%
|
84.50
|
| Capital Stock |
|
0.00
+100.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Common Stock |
|
0.00
+100.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Preferred Stock |
|
—
|
—
|
—
|
0.00
|
| Share Issued |
|
15.90
+15.33%
|
13.79
+0.41%
|
13.73
-1.82%
|
13.99
|
| Ordinary Shares Number |
|
15.49
+15.80%
|
13.38
-0.59%
|
13.46
-3.73%
|
13.98
|
| Treasury Shares Number |
|
0.41
+0.00%
|
0.41
+49.35%
|
0.28
+3367.87%
|
0.01
|
| Additional Paid In Capital |
|
713.30
+2.52%
|
695.78
+0.58%
|
691.77
-0.64%
|
696.22
|
| Retained Earnings |
|
-700.08
-5.94%
|
-660.82
-3.71%
|
-637.16
-5.20%
|
-605.64
|
| Gains Losses Not Affecting Retained Earnings |
|
-1.77
-47.83%
|
-1.20
-70.70%
|
-0.70
-135.98%
|
1.95
|
| Treasury Stock |
|
9.60
+0.00%
|
9.60
+2.94%
|
9.33
+16.13%
|
8.03
|
| Minority Interest |
|
—
|
0.00
-100.00%
|
22.36
-4.69%
|
23.46
|
| Other Equity Adjustments |
|
-1.77
-47.83%
|
-1.20
-70.70%
|
-0.70
-135.98%
|
1.95
|
| Total Equity Gross Minority Interest |
|
1.85
-92.34%
|
24.16
-63.90%
|
66.93
-38.00%
|
107.96
|
| Total Capitalization |
|
1.85
-95.70%
|
43.06
-3.40%
|
44.57
-47.25%
|
84.50
|
| Working Capital |
|
3.12
-92.67%
|
42.62
-24.46%
|
56.42
+15.65%
|
48.78
|
| Invested Capital |
|
20.24
-53.01%
|
43.06
-3.40%
|
44.57
-47.25%
|
84.50
|
| Total Debt |
|
22.14
+4.25%
|
21.24
+1480.28%
|
1.34
-37.95%
|
2.17
|
| Net Debt |
|
4.92
+171.36%
|
1.81
|
—
|
—
|
| Capital Lease Obligations |
|
3.76
+60.24%
|
2.34
+74.40%
|
1.34
-37.95%
|
2.17
|
| Net Tangible Assets |
|
1.61
-92.78%
|
22.33
-48.69%
|
43.51
-39.82%
|
72.30
|
| Tangible Book Value |
|
1.61
-92.78%
|
22.33
-48.69%
|
43.51
-39.82%
|
72.30
|
| Available For Sale Securities |
|
1.72
+2.08%
|
1.68
-45.15%
|
3.06
|
—
|
| Duefrom Related Parties Current |
|
0.00
-100.00%
|
0.59
|
0.00
|
—
|
| Financial Assets |
|
—
|
0.01
|
—
|
—
|
| Investmentin Financial Assets |
|
1.72
+2.08%
|
1.68
-45.15%
|
3.06
|
0.00
|
| Line Of Credit |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-29.22
-46.36%
|
-19.97
+5.32%
|
-21.09
+21.44%
|
-26.84
|
| Cash Flow From Continuing Operating Activities |
|
-29.22
-46.36%
|
-19.97
+5.32%
|
-21.09
+21.44%
|
-26.84
|
| Net Income From Continuing Operations |
|
-39.26
-49.50%
|
-26.26
+34.77%
|
-40.26
-12.32%
|
-35.84
|
| Depreciation Amortization Depletion |
|
2.33
-37.69%
|
3.74
+54.46%
|
2.42
+33.44%
|
1.81
|
| Depreciation |
|
1.27
-48.25%
|
2.45
+102.48%
|
1.21
+158.97%
|
0.47
|
| Amortization Cash Flow |
|
1.06
-17.56%
|
1.29
+6.36%
|
1.21
-10.17%
|
1.35
|
| Depreciation And Amortization |
|
2.33
-37.69%
|
3.74
+54.46%
|
2.42
+33.44%
|
1.81
|
| Amortization Of Intangibles |
|
1.06
-17.56%
|
1.29
+6.36%
|
1.21
-10.17%
|
1.35
|
| Other Non Cash Items |
|
—
|
—
|
1.19
-81.86%
|
6.55
|
| Stock Based Compensation |
|
1.31
-81.90%
|
7.22
+2.95%
|
7.01
-9.78%
|
7.77
|
| Asset Impairment Charge |
|
6.61
+120.62%
|
3.00
-69.77%
|
9.91
+362.14%
|
2.15
|
| Operating Gains Losses |
|
0.71
+266.67%
|
-0.43
+82.40%
|
-2.42
-494.84%
|
-0.41
|
| Gain Loss On Investment Securities |
|
—
|
—
|
-5.33
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
-1.70
-391.91%
|
0.58
-93.47%
|
8.89
+257.16%
|
-5.66
|
| Gain Loss On Sale Of PPE |
|
-0.48
|
0.00
-100.00%
|
2.06
+3066.15%
|
0.07
|
| Change In Working Capital |
|
0.77
+109.86%
|
-7.82
-17.56%
|
-6.65
-106.65%
|
-3.22
|
| Change In Receivables |
|
-5.21
-283.67%
|
2.83
+189.43%
|
-3.17
+38.54%
|
-5.16
|
| Changes In Account Receivables |
|
-5.79
-269.32%
|
3.42
+207.95%
|
-3.17
+38.54%
|
-5.16
|
| Change In Inventory |
|
5.83
+159.84%
|
-9.74
-130.18%
|
-4.23
-667.88%
|
-0.55
|
| Change In Prepaid Assets |
|
0.32
-54.49%
|
0.70
+150.69%
|
-1.38
-6.14%
|
-1.30
|
| Change In Payables And Accrued Expense |
|
-0.17
+89.54%
|
-1.61
-175.68%
|
2.13
-43.75%
|
3.79
|
| Change In Accrued Expense |
|
1.55
+276.48%
|
-0.88
+3.95%
|
-0.91
-139.60%
|
2.30
|
| Change In Payable |
|
-1.72
-132.07%
|
-0.74
-124.26%
|
3.05
+104.29%
|
1.49
|
| Change In Account Payable |
|
-1.72
-249.26%
|
1.15
+7.79%
|
1.07
-28.50%
|
1.49
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-0.05
|
| Investing Cash Flow |
|
11.24
+216.24%
|
-9.67
-131.04%
|
31.16
+250.59%
|
-20.69
|
| Cash Flow From Continuing Investing Activities |
|
11.24
+216.24%
|
-9.67
-131.04%
|
31.16
+250.59%
|
-20.69
|
| Net PPE Purchase And Sale |
|
-0.22
-9.31%
|
-0.20
+96.27%
|
-5.47
+38.74%
|
-8.94
|
| Purchase Of PPE |
|
-0.22
-9.31%
|
-0.20
+96.36%
|
-5.61
+37.26%
|
-8.95
|
| Sale Of PPE |
|
0.00
|
0.00
-100.00%
|
0.14
+1280.00%
|
0.01
|
| Capital Expenditure |
|
-0.24
+89.29%
|
-2.24
+60.07%
|
-5.61
+63.79%
|
-15.50
|
| Net Investment Purchase And Sale |
|
12.35
+246.51%
|
-8.43
-959.30%
|
-0.80
|
0.00
|
| Purchase Of Investment |
|
-1.41
+97.28%
|
-51.75
-1043.23%
|
-4.53
|
0.00
|
| Sale Of Investment |
|
13.76
-68.24%
|
43.32
+1061.14%
|
3.73
|
0.00
|
| Net Business Purchase And Sale |
|
-1.37
|
0.00
-100.00%
|
30.99
|
0.00
|
| Purchase Of Business |
|
-1.37
|
0.00
+100.00%
|
-2.90
|
—
|
| Net Intangibles Purchase And Sale |
|
0.48
+123.71%
|
-2.04
|
0.00
+100.00%
|
-6.55
|
| Purchase Of Intangibles |
|
-0.02
+99.17%
|
-2.04
|
0.00
+100.00%
|
-6.55
|
| Net Other Investing Changes |
|
—
|
1.00
-84.46%
|
6.44
+223.75%
|
-5.20
|
| Financing Cash Flow |
|
15.43
+1801.65%
|
-0.91
+72.24%
|
-3.27
-111.02%
|
29.64
|
| Cash Flow From Continuing Financing Activities |
|
15.43
+1801.65%
|
-0.91
+72.24%
|
-3.27
-111.02%
|
29.64
|
| Net Issuance Payments Of Debt |
|
0.00
|
0.00
|
0.00
+100.00%
|
-0.84
|
| Issuance Of Debt |
|
0.00
|
0.00
-100.00%
|
4.00
+464.32%
|
0.71
|
| Repayment Of Debt |
|
0.00
|
0.00
+100.00%
|
-4.00
-158.46%
|
-1.55
|
| Long Term Debt Issuance |
|
—
|
—
|
4.00
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
-4.00
-158.46%
|
-1.55
|
| Net Long Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-1.55
|
| Short Term Debt Issuance |
|
0.00
|
0.00
-100.00%
|
4.00
+464.32%
|
0.71
|
| Short Term Debt Payments |
|
0.00
|
0.00
+100.00%
|
-4.00
-158.46%
|
-1.55
|
| Net Short Term Debt Issuance |
|
0.00
|
0.00
|
0.00
+100.00%
|
-0.84
|
| Net Common Stock Issuance |
|
15.00
+5495.68%
|
-0.28
+91.49%
|
-3.27
-110.05%
|
32.50
|
| Common Stock Payments |
|
0.00
+100.00%
|
-0.28
+91.49%
|
-3.27
|
0.00
|
| Repurchase Of Capital Stock |
|
0.00
+100.00%
|
-0.28
+91.49%
|
-3.27
|
0.00
|
| Proceeds From Stock Option Exercised |
|
2.11
+1837.61%
|
0.11
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
-1.68
-127.37%
|
-0.74
|
—
|
-2.02
|
| Changes In Cash |
|
-2.55
+91.67%
|
-30.55
-548.96%
|
6.80
+138.03%
|
-17.89
|
| Effect Of Exchange Rate Changes |
|
-1.07
-306.37%
|
0.52
-67.71%
|
1.60
+442.00%
|
-0.47
|
| Beginning Cash Position |
|
17.08
-63.74%
|
47.11
+21.72%
|
38.70
-32.17%
|
57.06
|
| End Cash Position |
|
13.47
-21.16%
|
17.08
-63.74%
|
47.11
+21.72%
|
38.70
|
| Free Cash Flow |
|
-29.46
-32.67%
|
-22.21
+16.82%
|
-26.70
+36.94%
|
-42.34
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
-100.00%
|
0.06
+47.62%
|
0.04
|
| Income Tax Paid Supplemental Data |
|
0.00
-100.00%
|
1.81
|
0.00
|
0.00
|
| Change In Income Tax Payable |
|
0.00
+100.00%
|
-1.89
-195.35%
|
1.98
|
0.00
|
| Change In Tax Payable |
|
0.00
+100.00%
|
-1.89
-195.35%
|
1.98
|
0.00
|
| Common Stock Issuance |
|
15.00
|
0.00
|
0.00
-100.00%
|
32.50
|
| Earnings Losses From Equity Investments |
|
1.19
+2377.08%
|
0.05
-94.33%
|
0.85
|
0.00
|
| Issuance Of Capital Stock |
|
15.00
|
0.00
|
0.00
-100.00%
|
32.50
|
| Sale Of Business |
|
0.00
|
0.00
-100.00%
|
33.89
|
0.00
|
| Sale Of Intangibles |
|
0.50
|
0.00
|
0.00
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|